Rheonix Inc. Receives FDA Emergency Use Authorization for Rapid, Fully Automated Molecular COVID-19 Test
Sample-to-answer method will enable rapid testing in distributed locations
Read Press Release
Read Letter of Authorization
Mayor Richard C. David on Thursday joined John Carrigg, President and CEO of United Health Services (UHS), and Gregory J. Galvin, Ph.D., President and CEO of Rheonix Inc., to announce a same-day COVID-19 virus testing partnership between the City of Binghamton and United Health Services.
Read More »
Cayuga Medical Center to be First Hospital in NY State to Use This New Technology
Read More »
ITHACA, N.Y. – The discovery and development of microfluidic sensors hold great promise for the design of revolutionary diagnostic devices capable of complex analysis, in a disposable format, with minimal user intervention. However, many devices in this category have faced challenges to their widespread adoption.
Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, has successfully navigated the technological hurdles and solved many of the challenges in this area.… Read More »
ITHACA, N.Y. – While advancements in genetic testing have enabled rapid, more sensitive and specific methods to aid in the diagnoses and appropriate treatment of diseases including cancer, hemophilia, sickle cell anemia and cystic fibrosis, such advancements can come at a cost to both health care providers and patients. Molecular diagnostics executive Richard Montagna, Ph.D., vice president for scientific affairs for Rheonix Inc., an Ithaca-based developer of an automated molecular… Read More »
ITHACA, N.Y. –– Rheonix Inc., the developer of automated molecular diagnostic testing platforms, has been issued a patent protecting self-contained instruments for purifying, amplifying, and analyzing one or more target nucleic acid sequences necessary for performing a molecular test. The claims of the patent protect Rheonix’s EncompassMDx™ instrument. The instrument performs a wide range of molecular analyses using the Rheonix CARD® , which received international patent protection in 2012.
When used… Read More »
How have automation needs changed in the past few years?
Plank: In molecular testing, the desire among labs for greater efficiencies has increased the demand for automation and workflow advancements. More and more, labs are asking for platforms that offer more menu selection with less testing equipment. So the pattern of consolidation of platforms and menus is the same technological evolution we've seen over the last several years in clinical chemistry… Read More »
ITHACA, N.Y. – Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has appointed Bill Colston, Ph.D., to its board of directors. Colston, former CEO of QuantaLife Inc., led the development and product launch of Droplet Digital PCR™, a genetic analysis system for quantifying DNA molecules, until his company was acquired by Bio-Rad Laboratories in 2011.
As QuantaLife CEO, Colston raised multiple rounds of private funding and grew the company… Read More »
Ithaca, NY, June 14, 2012 – Rheonix, Inc. today announced that it will present data on its fully automated KRAS CARD™, the newest oncology application of the Company’s powerful molecular diagnostic platform. The KRAS CARD is designed to detect somatic mutations of the KRAS oncogene from either fresh or formaldehyde fixed-paraffin embedded (FFPE) tissue samples automatically on the EncompassMDx™ system. Patients undergoing colorectal cancer therapy are commonly screened, utilizing a… Read More »
Ithaca, NY – December 15, 2011 – Rheonix today announced that it has completed development of a novel microarray production technology to create a high-fidelity microarray, the Hy-Fi Microarray™. HyFi Microarrays provide simple, multiplexed end point detection for molecular assays and, in particular, a novel method to detect single nucleotide polymorphisms (SNPs) on the Rheonix CARD® system. While Rheonix intends to apply this proprietary microarray technology to improve SNP detection,… Read More »
Ithaca, NY – July 27, 2011 – Rheonix, Inc. today announced positive results in a new application of its powerful, automated, molecular diagnostic platform, termed SeptiCARD, for the detection of septicemia, the presence of bacteria in the blood often associated with severe infection. Results were presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Atlanta, Ga., July 24-28, 2011. These data continue… Read More »
Ithaca, NY – July 19, 2011 – Rheonix, Inc. today announced that data demonstrating the powerful, automated molecular diagnostic capabilities of the Rheonix CARD® system will be presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Atlanta, GA, July 24-28, 2011. Rheonix will also exhibit at the Clinical Lab Expo, Booth #4434.
“We now have a robust data set supporting our fully… Read More »
ROCHESTER, Minn. — Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories,… Read More »